Clinical trials: Steatotic Liver Disease
Fatty Liver
Association Between Fatty Liver and Inflammatory Biomarkers
The newly adapted definition for MASLD includes evidence for hepatic steatosis by imaging or biopsy with at least one of the five cardiometabolic criteria; BMI ≥ 25 kg/m2 (≥23 kg/m2 in Asian) or waist circumference >94 cm in men…
- Trial name
- MASLD (NCT07636915)
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Sohag University
MASLD, T2DM (Type 2 Diabetes Mellitus)
Non-Invasive MASLD Diagnosis & T2D Remission Biomarkers
The goal of this observational study is to prospectively develop and validate a non-invasive scoring system based on metabolic markers, proteomic, and transcriptomic profiles to accurately screen, diagnose, stage, and monitor…
- Conditions
- MASLD, T2DM (Type 2 Diabetes Mellitus), Non-alcoholic Fatty Liver Disease (NAFLD), Obesity
- Trial name
- ENSURE-MASLD (NCT07172997)
- Testing
- Bariatric Surgery
- Where
- 2 sites in Bahrain
- Volunteers
- 163 people
- Sponsor
- Royal College of Surgeons in Ireland - Medical University of Bahrain
Metabolic-dysfunction Associated Liver Disease (MASLD)
Testing a Multilevel, Culturally Appropriate Lifestyle Intervention For Hispanic Patients With Metabolic Dysfunction-associated Steatotic Liver Disease
The purpose of this study is to understand if a behavioral lifestyle intervention called the Healthy Liver/Hígado Sano program can help Hispanic/Latino patients with metabolic dysfunction associated steatotic liver disease…
- Trial name
- NCT07199491
- Testing
- Healthy Liver/Hígado Sano program, Usual Care
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- The University of Texas Health Science Center, Houston
HIV, Non-Alcoholic Fatty Liver Disease
The Gut, Liver And Metabolome in Human Immunodeficiency Virus and Non Alcoholic Fatty Liver Disease
Persons with human immunodeficiency virus (HIV) have higher risk of developing fatty liver disease (NAFLD) than HIV-negative persons but the reasons for this discrepancy are not known.
- Conditions
- HIV, Non-Alcoholic Fatty Liver Disease, Metabolic-Associated Steatotic Liver Disease
- Trial name
- GLAM HIV NAFLD (NCT06113003)
- Testing
- Prebiotic, Probiotic
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Vanderbilt University Medical Center
Metabolic Dysfunction-Associated Steatotic Liver Disease
Impact of Live Streaming Exercise on Liver Health in MASLD Pregnant Women
Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) is a clinical and pathological syndrome characterized primarily by excessive intracellular fat accumulation in the liver, excluding alcohol-related and other…
- Trial name
- NCT06682663
- Testing
- Live Streaming Exercise
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Peking University
MASLD, HIV (Human Immunodeficiency Virus)
Lipidomic and Multi-Omics Profiling of Fatty Liver Disease in People With and Without HIV
Metabolic dysfunction-associated steatotic liver disease (MASLD), commonly known as fatty liver disease, is increasingly prevalent worldwide.
- Trial name
- MASLD (NCT07640880)
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Yinzhong Shen
Metabolic Adaptation to High-Intensity Interval Training, Metabolic Associated-dysfunction Steatotic Liver Disease (MASLD)
Rehabilitation With Exercise-Based Intervention for Nonalcoholic Chronic Hepatic Esteatosis
This study proposes a single-blind randomized clinical trial designed to evaluate the effects of high-intensity interval training (HIIT) on liver health in adults with overweight or obesity, while also assessing the usefulness of…
- Trial name
- RENACE (NCT07552727)
- Testing
- High-intensity interval training
- Where
- Chile
- Volunteers
- 30 people
- Sponsor
- Universidad San Sebastián
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, MASH - Metabolic Dysfunction-Associated Steatohepatitis
Exercise for an Aging Liver (EXALIVER)
The goal of this clinical trial is to learn how physical exercise affects liver health in adults with metabolic dysfunction-associated steatotic liver disease (MASLD) or at-risk metabolic dysfunction-associated steatohepatitis…
- Conditions
- MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, MASH - Metabolic Dysfunction-Associated Steatohepatitis, Liver Fibrosis/NASH
- Trial name
- EXALIVER (NCT07467512)
- Testing
- Exercise, Usual Care
- Where
- Spain
- Volunteers
- 40 people
- Sponsor
- Consorcio Centro de Investigación Biomédica en Red (CIBER)
Metabolic Dysfunction-Associated Steatotic Liver Disease
Efficacy and Safety of Rifaximin-α in Treating MASLD
Study Objective: To evaluate the efficacy and safety of Rifaximin-α in the treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), and investigate the underlying mechanisms by which Rifaximin-α influences…
- Trial name
- NCT07381257
- Testing
- Rifaximin-α (Alfa Wassermann S.p.A., Italy)
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shanghai Changzheng Hospital
Metabolic Dysfunction-Associated Steatotic Liver Disease, Type 2 Diabetes (T2DM)
The Establishment of Hong Kong Diabetes Steatotic Liver Disease Register
Liver is an important organ in maintaining energy homeostasis. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is the most common chronic liver…
- Trial name
- NCT07437157
- Testing
- No intervention (observational study)
- Where
- Hong Kong
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Chinese University of Hong Kong
Metabolic Dysfunction-Associated Steatotic Liver Disease
Using Digital Twin Technology and Clinical Decision Support Systems to Improve the Early Detection, Personalised Treatment, and Long-term Monitoring of Patients Across the Full Spectrum of Metabolic-associated Fatty Liver Disease (MAFLD).
The goal of this observational study is to create a detailed virtual model to better understand how Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) develops.
- Trial name
- ARTEMIS (NCT07430501)
- Testing
- Data recollection
- Where
- Spain
- Volunteers
- 7,720 people, healthy volunteers welcome
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Obstructive Sleep Apnea (OSA), Metabolic Dysfunction-Associated Steatotic Liver Disease
FIB-4 Index, Sleep Apnea Severity, and Nocturnal Hypoxemia
This retrospective study evaluates whether the Fibrosis-4 (FIB-4) index is associated with the severity of obstructive sleep apnea (OSA) and nighttime oxygen desaturation.
- Trial name
- FIB-4-OSA (NCT07798518)
- Where
- Turkey (Türkiye)
- Volunteers
- 373 people
- Sponsor
- Hisar Intercontinental Hospital
Nonalcoholic Fatty Liver, Osteoporosis, Postmenopausal
Effect of Anti-osteoporotic Medications on Nonalcoholic Fatty Liver Disease
Nonalcoholic fatty liver disease (NAFLD) is a chronic, metabolic liver disease that is closely related to obesity, type 2 diabetes mellitus (T2DM) and metabolic syndrome (MetS) in a bidirectional mode.
- Trial name
- OsteoNAFLD (NCT05493761)
- Testing
- Denosumab, Alendronate Sodium
- Where
- 3 sites in Greece
- Volunteers
- 72 people
- Sponsor
- Aristotle University Of Thessaloniki
Metabolic Dysfunction-Associated Steatotic Liver Disease, Hepatic Steatosis
Quantitative Ultrasound (RS85 and R20) for Liver Fat Quantification in MASLD Using MRI-PDFF as Reference
This multicenter prospective study aims to evaluate the correlation between quantitative ultrasound fat fraction (USFF) and MRI-PDFF (Proton Density Fat Fraction) for liver fat quantification in patients with metabolic…
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease, Hepatic Steatosis, Liver Disease Parenchymal
- Trial name
- DeepUSFF (NCT07192159)
- Testing
- Quantitative ultrasound (DeepUSFF)
- Where
- 2 sites in United States, South Korea
- Volunteers
- 182 people
- Sponsor
- Seoul National University Hospital
Steatotic Liver Disease, Liver Fibrosis Progression in Chronic Liver Disease
Interventional AI-Human Collaboration for Steatotic Liver Disease Screening
Steatotic liver disease (SLD) is one of the most prevalent chronic liver diseases worldwide, affecting nearly 30% of the global population and projected to exceed 55% by 2040.
- Conditions
- Steatotic Liver Disease, Liver Fibrosis Progression in Chronic Liver Disease, Liver Steatosis, Liver Fibrosis
- Trial name
- NCT07613827
- Testing
- AI-human collaboration for SLD screening
- Where
- China
- Volunteers
- 7,969 people, healthy volunteers welcome
- Sponsor
- Shengjing Hospital
Metabolic Dysfunction-Associated Steatotic Liver Disease, Hepatocellular Carcinoma
Prognostic Factors for HCC and Liver Transplantation in Patients With MASLD/MASH
The BOMASH study is a single-center, prospective/retrospective observational study without pharmacological interventions. It will include all patients diagnosed with Metabolic-Associated Steatotic Liver Disease (MASLD/MASH)…
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease, Hepatocellular Carcinoma, Metabolic Dysfunction-Associated Steatohepatitis, Liver Transplant
- Trial name
- BOMASH (NCT06813508)
- Where
- Italy
- Volunteers
- 1,000 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Metabolic Dysfunction-Associated Steatotic Liver Disease, Childhood Obesity
Lifestyle Habits and Metabolic Dysfunction-Associated Steatotic Liver Disease in Youth
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is the most common cause of chronic liver disease in children and adolescents.
- Trial name
- LIFE4MASLD (NCT07095010)
- Where
- Greece
- Volunteers
- 224 people, healthy volunteers welcome
- Sponsor
- Harokopio University
Metabolic Dysfunction Associated Steatotic Liver Disease, Overweight (BMI > 25)
Feasibility of the Paso Program for Patients With Metabolic Dysfunction Associated Steatotic Liver Disease
The purpose of this study is to learn whether the Paso weight loss program is feasible for Mexican and Central American patients with fatty liver disease.
- Conditions
- Metabolic Dysfunction Associated Steatotic Liver Disease, Overweight (BMI > 25), Metabolic Syndrome
- Trial name
- NCT06854185
- Testing
- Paso Program
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Baylor College of Medicine
Non-Alcoholic Fatty Liver Disease, Steatosis of Liver
Improving Diagnostic Safety Through STeatosis Identification, Risk Stratification, and Referral in the ED
Hepatic steatosis is a common radiographic "incidental finding" that is overlooked and underreported to patients. The investigators developed a clinical decision support system using machine learning and natural language…
- Conditions
- Non-Alcoholic Fatty Liver Disease, Steatosis of Liver, Metabolic Dysfunction-Associated Steatotic Liver Disease
- Trial name
- STIRRED (NCT06944353)
- Testing
- STIRRED
- Where
- United States
- Volunteers
- 4,704 people
- Sponsor
- Northwestern University
Fatty Liver, Nonalcoholic
Probiotic Supplement Versus Placebo for the Treatment of Patients With Non-alcoholic Fatty Liver Disease
Probiotic supplement versus placebo for the treatment of patients with non-alcoholic fatty liver disease: a randomized, double-blind, placebo-controlled trial
- Trial name
- NCT06491342
- Testing
- Probiotic
- Where
- 2 sites in Thailand
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Phramongkutklao College of Medicine and Hospital